Business description
Ryvu Therapeutics is developing therapeutics that address clinical limitations of current treatments in oncolog.
Their lead candidate, RVU120, is a selective CDK8/CDK19 kinase inhibitor with potential for development in hematological malignancies and solid tumors, currently in Phase 1b study for the treatment of acute myeloid leukemia and myelodysplastic syndrome, and Phase I/II for the treatment of r/r metastatic or advanced solid tumors. SEL24 (MEN1703) is a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group, in Phase 2 clinical development for the treatment of acute myeloid leukemia.
Management board & Supervisory board
| CEO |
| Paweł Przewięźlikowski |
| Management board |
| Vatnak Vat-Ho, Hendrik Nogai, Kamil Sitarz, Krzysztof Brzózka |
| Supervisory board |
| Piotr Romanowski, Tadeusz Wesołowski, Rafał Chwast, Axel Glasmacher, Jarl Jungnelius, Thomas Turalski |
Company data
| Name: |
RYVU THERAPEUTICS S.A. |
| Address: |
Leona Henryka Sternbacha 2,30-394 Kraków |
| Phone: |
+48 12 314 02 00 |
| Fax: |
+48 12 297 47 01 |
| E-mail: |
ryvu@ryvu.com
|
| Internet: |
https://ryvu.com/ |
| Industry: |
Biotechnology |
| Sector: |
Biotechnology |
| Sub sector: |
- |
| End of financial year: |
12/31 |
| Free Float: |
74.30% |
| IPO date: |
7/14/2011 |
Investor relations
| Name: |
- |
| IR phone: |
- |
| IR Fax: |
- |
| IR e-mail: |
ir@ryvu.com
|
